# Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

> **NCT00513292** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 280 (actual)

## Conditions studied

- HER2/Neu Positive
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **PROCEDURE:** Therapeutic Conventional Surgery
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT00513292
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2012-06
- **Final completion:** 2013-02-21
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2019-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513292, "Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00513292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*